Suppr超能文献

长期抑制DNA合成以及被困拓扑异构酶II复合物的持续存在在决定抗肿瘤DNA嵌入剂mAMSA和米托蒽醌的毒性方面的作用。

Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.

作者信息

Fox M E, Smith P J

机构信息

Medical Research Council Clinical Oncology, Medical Research Council Centre, Cambridge, United Kingdom.

出版信息

Cancer Res. 1990 Sep 15;50(18):5813-8.

PMID:2168281
Abstract

The cytotoxic actions of several classes of antitumor DNA intercalators are thought to result from some disturbance to DNA metabolism following trapping of the nuclear enzyme DNA topoisomerase II as a covalent complex on DNA. Here we have studied topoisomerase II trapping and DNA synthesis patterns in relation to the acute cytotoxic actions of 4'-(9-acridinylamino)methanesulfon-m-anisidide (mAMSA) or mitoxantrone on SV40 transformed human fibroblasts. These two DNA intercalators differed significantly in their cytotoxic potential, mitoxantrone being 24-fold more toxic than mAMSA when assayed by the inhibition of clonogenicity. Although both drugs induced G2 delay at cytotoxic concentrations, mAMSA-treated cells recovered normal cell cycle phase distributions within 24 h of removal of drug, while mitoxantrone-treated cells continued to accumulate in G2 up to 48 h following drug treatment with evidence of complete inhibition of entry into mitosis. Compared with mAMSA, mitoxantrone showed a similar capacity to induce cleavable complexes in cellular DNA, and only a 2-fold greater ability to inhibit DNA synthesis. Within a 4-h posttreatment period, mAMSA-treated cells recovered normal rates of DNA synthesis, whereas a continued depression of DNA synthesis was observed in mitoxantrone-treated cells. The recovery patterns of DNA synthesis correlated with the rapid disappearance of mAMSA-induced complexes (less than 27% lesions remaining 2 h after drug removal) and the persistence of mitoxantrone-induced complexes during a 4-h posttreatment period. This difference in complex longevity was observed in other human transformed fibroblast cell lines irrespective of differences in the absolute levels of complexes induced by either agent. We suggest that the results provide evidence that DNA intercalators may differ in the forms of complexes induced and that the comparatively high cytotoxicity of mitoxantrone relates to the ability of the drug to trap topoisomerase II complexes in a form which effects a long-term inhibition of DNA replication and G2 traverse.

摘要

几类抗肿瘤DNA嵌入剂的细胞毒性作用被认为是由于核酶DNA拓扑异构酶II作为共价复合物被困在DNA上后,对DNA代谢产生了某种干扰所致。在此,我们研究了拓扑异构酶II的捕获情况以及与4'-(9-吖啶基氨基)甲磺酰间茴香胺(mAMSA)或米托蒽醌对SV40转化的人成纤维细胞的急性细胞毒性作用相关的DNA合成模式。这两种DNA嵌入剂在细胞毒性潜力方面存在显著差异,通过克隆形成抑制试验测定时,米托蒽醌的毒性比mAMSA高24倍。尽管两种药物在细胞毒性浓度下均诱导G2期延迟,但mAMSA处理的细胞在去除药物后24小时内恢复了正常的细胞周期阶段分布,而米托蒽醌处理的细胞在药物处理后长达48小时内持续在G2期积累,并有进入有丝分裂完全受抑制的证据。与mAMSA相比,米托蒽醌在细胞DNA中诱导可裂解复合物的能力相似,抑制DNA合成的能力仅高2倍。在处理后4小时内,mAMSA处理的细胞恢复了正常的DNA合成速率,而米托蒽醌处理的细胞中观察到DNA合成持续受到抑制。DNA合成的恢复模式与mAMSA诱导的复合物快速消失相关(药物去除后2小时残留损伤不到27%),以及米托蒽醌诱导的复合物在处理后4小时内持续存在。在其他人类转化的成纤维细胞系中也观察到了复合物寿命的这种差异,而与两种药物诱导的复合物绝对水平的差异无关。我们认为,这些结果提供了证据表明DNA嵌入剂诱导的复合物形式可能不同,并且米托蒽醌相对较高的细胞毒性与该药物以影响DNA复制和G2期进程长期抑制的形式捕获拓扑异构酶II复合物的能力有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验